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Purpose—In this longitudinal study we explored the relationships between plasma n-3 and n-6 
polyunsaturated fatty acids (PUFAs) and Δ5 and Δ6 desaturase activities (D5D and D6D, 
respectively) and fasting lipids in youth with type 1 diabetes (T1D).
Methods—Incident cases of T1D in youth <20 years of age who were seen for a baseline study 
visit (N=914) and a 1-year follow-up visit (N=416) were included. Fasting blood samples were 
obtained at each visit and plasma phospholipid n-6 PUFAs were measured, which included linoleic 
acid (LA), dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA); n-3 PUFAs included α-
linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Estimated 
D5D and D6D were calculated as FA product-to-precursor ratios, where D5D= AA/DGLA and 
D6D = DGLA/LA. To examine the longitudinal relationships between long chain PUFAs, 
desaturase activities and fasting plasma lipids in youth with T1D mixed effects models were used 
for each individual PUFAs, D5D and D6D, adjusted for demographics, clinic site, diabetes 
duration, insulin regimen, insulin dose/kg, HbA1c, insulin sensitivity score, and body mass index 
with random effects to account for the repeated measurements.
Findings—Favorable lipid associations were found between LA and low-density lipoprotein 
(LDL) cholesterol (β= −0.58, P<0.05); AA, plasma triglycerides (TG) (β= −0.04, P<0.05) and TG/ 
high-density lipoprotein (HDL)-C ratio (β= −0.04, P<0.05); and D5D, plasma TG (β= −0.2, 
P<0.05) and TG/HDL-cholesterol ratio (β= −0.23, P<0.05). Findings were mixed for the n-3 
PUFAs and DGLA: ALA was positively associated with plasma TG (β= 0.33, P<0.05) and HDL 
cholesterol (β= 9.86, P<0.05); EPA was positively associated with total cholesterol (β= 8.17, 
P<0.05), LDL cholesterol (β=5.74, P<0.01) and HDL cholesterol (β= 2.27, P<0.01); and DGLA 
was positively associated with TG/HDL-cholesterol ratio (β= 0.05, P<0.05)
Conclusion—Findings suggest that the most abundant PUFA, LA as well as its metabolic bi-
product AA, may be important targets for CVD lipid risk factor reduction in youth with T1D.
Keywords
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1. Introduction
Dietary intake of n-3 and n-6 polyunsaturated fatty acids (PUFAs) may have beneficial 
effects on cardiovascular health, although some controversy exists in this regard. For 
example, observational and intervention studies have shown that long chain n-3 PUFAs tend 
to reduce serum triglycerides (TG), but may increase low density lipoprotein (LDL) 
cholesterol (C) (1, 2). Further, cross-sectional analysis and controlled trials show diets rich 
in n-6 PUFAs lower LDL-C, but may also lower high density lipoprotein (HDL)-C (3, 4). 
Increasing PUFA dietary intake has been associated with positive health outcomes in healthy 
individuals without diabetes (1, 2, 4). Current recommendations for individuals at high risk 
for cardiovascular disease (CVD), including those with diabetes, support increasing food 
sources of n-3 PUFAs including α-linolenic acid (ALA, 18:3n-3), eicosapentanoic acid 
(EPA, 20:5n-3), and docosahexanoic acid (DHA, 22:6 n-3) to favorably alter serum lipids 
and for the prevention of heart disease (5). However few studies exist showing health 
benefits in individuals with diabetes, particularly those with type 1 diabetes (T1D).
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PUFAs modify plasma lipids through several intracellular mechanisms including modulation 
of cellular signaling pathways and transcription factors that control fatty acid synthesis, beta 
oxidation, and lipid transport and clearance (3, 6). Total plasma PUFAs can alter lipid 
metabolism, but individual circulating PUFAs exert differential effects such that the relative 
proportion of one PUFA compared to another, even within the same class (n-3 or n-6), may 
impact health and well-being (3, 4). As evidence, several clinical studies have shown that the 
n-6 PUFA di-homo- γ - linolenic acid (DGLA, 20:3n-6) but not the less saturated n-6 PUFA 
arachidonic acid (AA, 20:4n-6) was related to dyslipidemia and a high degree of insulin 
resistance in patients with type 2 diabetes (T2D) (3, 4). While dietary intake of n-3 and n-6 
PUFA is an important determinate of the relative amount of these fatty acids in vivo, long 
chain PUFAs can be further metabolized endogenously (see Figure 1). Therefore, activities 
of enzymes that regulate fatty acid desaturation processes also play a critical role in the 
availability of long chain n-3 and n-6 PUFAs. Product-to-precursor ratios of certain PUFAs 
can be used to estimate enzyme activity of desaturases involved in PUFA metabolism (7), 
and applying these ratios may be of particular relevance to diabetes risk management, as 
insulin induces the genes encoding desaturase enzymes (7, 8). For example, acute 
hypoinsulinemia that often accompanies T1D has been shown to contribute to altered 
desaturase levels and lower endogenous formation of PUFAs (9). Whether these metabolic 
perturbations resulting in dysregulation of PUFA metabolism also have adverse effects on 
plasma lipids of individuals with T1D has not been investigated.
Presently, longitudinal studies are lacking on relationships between long chain PUFAs, 
desaturase activities and fasting plasma lipids in youth with T1D. In the current study, we 
examined these associations in a large, multi-ethnic sample of youth with T1D. In these 
analyses, consideration was given to relevant confounders such as hemoglobin A1c 
(HbA1c), insulin treatment regimen, and body mass index (BMI) to provide a more precise 
estimate of the relationships between n-3 and n-6 PUFAs and each lipid parameter.
2. Methods
2.1. Participants
The SEARCH for Diabetes in Youth study is an ongoing multi-center, observational study of 
the epidemiology of childhood diabetes (10). Additional diet data were collected by the 
SEARCH Nutrition Ancillary Study (SNAS), funded in 2008 with data collection completed 
in 2011, designed to test hypotheses related to nutritional determinants of CVD risk in youth 
with T1D. Both SEARCH and SNAS are reviewed and approved annually by local 
institutional review boards that have jurisdiction over the local study populations. Parents of 
participants under age 18 years at the time of data collection provided written informed 
consent and age-eligible participants provided assent; all participants aged 18 years or older 
provided written informed consent.
The present study was a longitudinal analysis of data from the 2002–2005 incident cohort in 
the main SEARCH study. Data were available on 977 children 1–20 years of age with T1D 
who participated in the SEARCH baseline exam. Included participants had plasma PUFAs 
and fasting plasma lipid data at the initial visit. Participants excluded from analysis included: 
T1D duration <3 months at baseline (N=58); fasting lipids not available at baseline (N=1); 
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hypertriglyceridemia at baseline (TG>400 mg/dl, N=1); and outlying plasma PUFAs values 
(> 3 IQR above the 75th percentile or 3 IQR <25th percentile, N=3). This yielded an N=914 
at baseline; 419 of these had 12-month follow-up fatty acid and fasting lipid data available. 
Three follow-up samples were excluded due to hypertriglyceridemia yielding a final follow-
up sample of N=416.
2.2. Data Collection
Participants were invited to attend an in-person baseline exam where demographic, 
anthropometric, laboratory and clinical data were collected. Those who completed the 
baseline exam where subsequently invited to participate in a follow-up visit 1-year later 
consisting of the same elements as the baseline exam. Blood samples were obtained under 
conditions of metabolic stability, defined as no episode of diabetic ketoacidosis during the 
previous month. Specimens were processed at the site and shipped within 24 hours to the 
Northwest Lipid Metabolism and Diabetes Research Laboratories in Seattle, Washington. 
All measures were conducted by trained, certified staff in accordance with standardized 
study protocols (available at www.searchfordiabetes.org). A more detailed description of the 
measures considered in the present study is described in the following sections.
2.3. Outcomes
Plasma lipid profiles—Measurement of plasma cholesterol (C), TG, and HDL- C were 
performed enzymatically on a Hitachi 917 autoanalyzer (Boehringer Mannheim Diagnostics, 
Indianapolis, IN). LDL- C was calculated by the Friedewald equation (11). The ratio of TG 
to HDL-C was calculated as a predictor of small, dense LDL particle size (12).
2.4. Exposures
PUFAs: total lipids were extracted by the Bligh Dyer method and phospholipids (PLs) were 
separated from all other lipids by one dimensional thin layer chromatography. The PL 
extract was then saponified and trans-methylated using the method of Tacconi and Wurtman 
(13). Gas chromatography was performed on samples dissolved in undecane using 
conditions modified from Lemaitre et al (14). Data were analyzed with ChemStation 
Firmware A.01.09 (Agilent Technologies Inc., Palo Alto CA). The coefficients of variation 
in the quality control pooled samples were as follows: 2% for linoleic acid (LA, 18:2n-6), 
5.7% for DGLA, 2.7% for AA, 9.6% for ALA, 9.9% for EPA and 11.5% for DHA. Details 
of the methods are published elsewhere (15). Individual plasma PLs are expressed as 
percentage (by weight) of total fatty acids detected. Desaturase activities: delta 5 desaturase 
(D5D) and delta 6 desaturase (D6D) activities were estimated from product-to-precursor 
ratios of individual fatty acids in plasma PL. In this study, D5D activity = AA /DGLA and 
D6D = DGLA /LA. Estimation of desaturase activity using this approach is well accepted in 
the literature (16).
2.5. Covariates
Demographics: were self-reported and included birth date, gender, race/ethnicity, highest 
level of parent education in the household, and diabetes related factors (duration of disease, 
insulin regimen type, units of insulin/kg, clinical site). BMI: weight and height were 
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measured twice in a standardized manner and averaged. BMI was calculated as weight in kg 
divided by height in m2, and age and gender specific BMI z-scores were derived based on 
the Centers for Disease Control and Prevention national standards (17). HbA1c: was 
measured on whole blood samples with an automated ion-exchange high-performance liquid 
chromatography instrument (Tosoh Bioscience, Montgomeryville, PA). Insulin sensitivity 
score (ISS): a surrogate measure of insulin resistance was estimated using the following 
equation: loge ISS = 4.64725 – 0.02032 (waist circumference, cm)–0.09779 (HbA1c, %)–
0.00235 (TG, mg/dl). A detailed description of the development and validation of this 
equation has been published elsewhere (18).
2.6. Statistical analysis
Statistical analyses were performed using SAS for Windows (version 9.2; SAS Institute, 
Cary NC). There were 914 individuals in the dataset and N=32 were missing ALA, N=8 
were missing EPA and N=1 was missing DGLA. Missing fatty acid percentages may result 
from an undetected peak, which is associated with a small value. Ignoring these unobserved 
values from the dataset can cause bias. The literature suggests that when observations are 
undetectable (Environmental Protection Agency guideline suggests <15%) (19), it is 
appropriate to impute the non-detects with a small number; half the detection limit is a 
common choice. The detection limit for these data is not well-defined, as the units are 
“percent of total” and may vary across individuals. To circumvent this, we replaced the non-
detectable values for ALA and DGLA with half the lowest observed value. As previously 
described, DGLA was used in the estimation of D5D and D6D, and the use of the imputed 
value yielded an outlier in both cases. Consequently, the missing desaturase value was not 
imputed. The final sample size was N=914 for each fatty acid and N=913 for each 
desaturase. At follow-up, there were 416 observations available for each fatty acid (i.e., 
neither the participant with the outlying D5D or the missing DGLA had a follow-up 
measure).
Demographic characteristics were described with means and standard deviations (SD) for 
continuous variables and frequencies for categorical variables. Log transformations were 
used for triglycerides, the proportions of EPA and DHA in plasma PL, and estimated D5D 
and D6D activities to improve normality as residuals. A mixed effects model was fit for the 
relationship between fatty acid or desaturase exposure and concurrent outcome. The mixed 
effects model allows for correlation between observations within a participant. Two models 
were fit: unadjusted and adjusted for demographics (age, gender, race, parent education, 
clinic site), diabetes-related factors (disease duration, insulin regimen type, insulin dose per 
kilogram, HbA1c and insulin sensitivity score), and BMI z-score. A third model was run on 
a subset of participants with available food frequency data (for children >10 years; N=491 at 
baseline and N=207 at 1-year). For the third model, the adjusted repeated measures model 
was re-fit for each PUFA and plasma lipid outcome to include saturated fat intake. All 
models included random effects to account for the repeated measurements. Statistical 
significance of each nutritional exposure/lipid relationship was established with p<0.05.
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3. Results
Demographics and clinical characteristics of the population studied are shown in Table 1. 
Our sample consisted of 914 youth with T1D who were predominately Caucasians with a 
mean age of 11 years and who were, on average, 10.9 months post-diagnosis. Forty-five 
percent were managed with basal bolus regimens including insulin pump therapy or a 
combination of long + short/rapid acting insulin with injections 3 or more times per day. 
Average HbA1c values were 7.8% with 11.2% (N=100) having HbA1c in excess of 9.5%. 
Table 2 shows the relative proportion of individual PUFAs in plasma PL, D5D and D6D 
activities estimated by fatty acid product-to-precursor ratios, and lipid profiles of the sample.
Results of mixed effects models to examine associations between PUFAs, desaturases and 
lipid outcomes are shown in Table 3 and Table 4. In unadjusted models (Table 3), favorable 
associations were found for the following n-6 PUFAs, desaturases and lipids: LA was 
positively related with HDL-C (p<0.01); AA was negatively associated with TG (p<0.05), 
total C (p<0.01) and TG/HDL-C ratio (p<0.05); DGLA and D6D were negatively associated 
with total C (p<0.01 for both); and D5D was negatively related with TG (p<0.05) and TG/
HDL-C ratio (p<0.05) and positively associated with HDL-C (p<0.01). Of the n-6 PUFAs, 
only DGLA showed an adverse lipid association with HDL-C (p<0.05) and TG/HDL-C 
(p<0.05). For the n-3 PUFAs, adverse lipid associations were found for ALA and EPA. 
Specifically, ALA was positively associated with TG (p<0.05), total C (p<0.01) and TG/
HDL-C ratio (p<0.05) and EPA was positively associated with total C (p<0.01) and LDL–C 
(p<0.01).
In adjusted models (Table 4), the overall finding of favorable lipid associations with LA, AA 
and D5D remained; mixed effects for the n-3 PUFAs, DGLA and D6D were identified. 
Specifically, LA was negatively associated with LDL-C (p<0.05); AA was negatively 
associated with TG (p<0.05) and TG/HDL-C ratio (p<0.05); and D5D was inversely 
associated with TG (p<0.05) and TG/HDL-C ratio (p<0.05). For the n-3 PUFAs, ALA was 
positively associated with TG (p<0.05) and HDL-C (p<0.05); EPA was positively associated 
with total C (p<0.05), LDL–C (p<0.01), and HDL-C (p<0.05); and DHA was positively 
associated with LDL-C (p<0.05). For DGLA and D6D, positive associations with TG/HDL-
C ratio (p<0.05) were identified.
Given the unexpected adverse relationships between the n-3 PUFAs and plasma lipids and to 
determine whether saturated fat intake could be a potential mediator for these observed 
associations, adjusted models were re-fit to include dietary saturated fat intake (grams/day) 
in the subset of the sample with food frequency data available. The adjustment for saturated 
fat did not change any of the findings of significance as reported in Table 4 (data not shown). 
For all models except AA and total C, the beta coefficients changed less than 0.5% and the 
p-values for these relationships remained unchanged to 3 decimal places. For AA and total 
C, the beta coefficient changed 13%, however the effect was not significant.
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4. Discussion
There is ongoing debate regarding the cardiovascular effects of n-3 and n-6 PUFAs and key 
enzymes involved in their metabolism. The debate stems from controversial evidence 
regarding whether too much of these fatty acids and the relative dietary proportion of each 
may have beneficial or adverse effects on the cardiovascular system (1–4). This debate is 
clinically relevant to youth with T1D who are prone to CVD and its complications (20). A 
major finding from the present analyses was that the n-6 PUFAs LA and AA were favorably 
associated with plasma lipids after adjustment for important demographic and clinical 
characteristics, whereas findings were mixed relative to DGLA and the n-3 PUFAs. 
Desaturase activities were related to plasma lipids, but not in a similar manner, suggesting 
different functional roles for D5D and D6D relative to lipid metabolism. These results 
suggest that desaturase activities and plasma PL PUFA profile of youth with T1D may be 
important targets for CVD lipid risk factor reduction in this at-risk population.
In this study, a higher proportion of the n-6 PUFAs LA and AA were related to lower LDL-
C and TG concentrations, respectively, suggesting a CVD protective effect. AA was also 
inversely related to TG/HDL-C ratio, a predictor of atherogenic small, dense LDL-C (12). In 
contrast, the n-6 PUFA DGLA, which is the precursor to AA (see Figure 1), was directly 
related to the TG/HDL-C ratio. This finding suggests that regulation of D5D activity, which 
catalyzes the desaturation of DGLA to AA, may be an important determinant of the TG/
HDL-C ratio and LDL particle size in T1D. In the literature, some (21, 22) but not all studies 
(4, 23) have shown n-6 PUFAs are related to beneficial effects on plasma lipids. Recent data 
from the HEPFAT trial (24) showed that high intake of n-6 PUFAs were related to a decrease 
in cholesterol biosynthesis and low hepatic fat content and exportation, which may explain 
our findings of favorable n-6 PUFA relationships with plasma lipids. From our results, the 
calculated LDL-cholesterol lowering effect from LA was small (1.6 mg/dl change in LDL-
cholesterol per unit change in LA). Whether this effect is clinically meaningful remains to 
be determined. Dietary LA is the most abundant of the n-6 PUFA (25), derived from 
vegetable oils. In randomized controlled trials, safflower and corn oil, which are richest in 
LA, were shown to have the most potent cholesterol lowering effects of the vegetable oils 
(22). Preformed AA is limited and derived from animal products such as meats, poultry and 
eggs. LA can be endogenously converted to AA after successive desaturation and elongation 
reactions, but this conversion is limited in humans (Figure 1) (26). Therefore, determining 
alternative methods to increase plasma PL AA may be important for CV risk reduction, 
although some caution is needed as AA can also be endogenously converted to bioactive 
eicosanoids, which produce chemical mediators that have diverse inflammatory and immune 
modulating effects (4, 27).
The unfavorable positive association between the n-3 PUFA ALA and blood TG in our study 
was unexpected, but very little research has been done with ALA specifically (28). The 
literature supports a TG lowering effect of the longer chain n-3 PUFAs EPA and DHA (1, 2); 
however the TG lowering effects usually occur with supplemental doses of EPA and DHA in 
the range of 2–4 g/day (29, 30) and ALA is not typically evaluated. No prior information 
exists between ALA and plasma lipids in youth with T1D, although several researchers have 
shown higher levels of plasma PL ALA and lower EPA and DHA in T1D adults compared to 
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healthy controls suggesting altered synthesis of LC n-3 PUFAs from the precursor ALA (31, 
32). Therefore, imbalances in EPA/DHA to ALA ratios in this sample due to disease related 
factors may provide some explanation for the unexpected findings. Alternatively, ALA may 
have its own specific physiological effects relative to lipid metabolism that are independent 
of being a precursor for EPA (33, 34). Others have shown that in contrast to EPA and DHA, 
fasting VLDL concentrations were not reduced with ALA feeding (34). Decreased hepatic 
synthesis of VLDL is the primary mechanism whereby EPA and DHA exert TG lowering 
effects (6). A related increase in the activity of lecithin-cholesterol acyl-transfer protein by 
ALA, as seen by others (35), could explain the favorable positive association between ALA 
and HDL-cholesterol in the present study. This enzyme promotes the esterification and 
internalization of cholesterol into HDL, thereby increasing HDL-C levels.
Our findings that PL EPA and DHA were unfavorably related to LDL-C and that PL EPA 
was favorably related to HDL-C and unrelated to TG is in line with several recent reviews of 
the controversial effects of EPA and DHA on plasma lipids in healthy individuals (36, 37). 
LC n-3 PUFAs are thought to modify plasma lipids in a number of ways, including 
decreasing hepatic VLDL TG synthesis through modulation of transcription factors (e.g., 
SREBP-1c and PPARα) involved in lipogenic and beta-oxidation pathways (38). N-3 PUFAs 
also reportedly increase lipoprotein lipase activity, promoting increased clearance of TG and 
conversion of VLDL to LDL (39). This is thought to be the likely mechanism for the LDL-
raising effect of LC n-3 PUFAs (37). Additionally, cholesterol ester transfer protein has been 
shown to be increased by EPA and DHA leading to enhanced lipid exchange between LDL 
and HDL particles (39). In most studies, alterations in the function of these enzymes and 
transcription factors are achieved when supplemental doses of EPA and DHA are provided 
(3). Although supplementation does not explain the findings of the present investigation, it is 
possible that those with relatively high EPA in the sample also had a higher proportion of 
saturated fat in the diet. A positive relationship between saturated fat, LDL-C and HDL-C is 
well established (40). To determine whether the relationship between EPA and LDL- and 
HDL-C observed in the present study could be mediated by dietary saturated fat intake, we 
re-fit our adjusted repeated measures models for EPA and plasma lipids to include saturated 
fat intake from a subset of participants with available food frequency data (n=497). Findings 
from this sub-analysis do not support saturated fat as a likely explanation of our results.
Similar to previous studies in healthy adolescents (20), our results show a favorable 
association between estimated D5D and plasma lipids, whereas adverse associations were 
found for D6D. D5D and D6D activities may have divergent effects on the FA composition 
of cell membranes, which affect many aspects of glucose control including insulin receptor 
binding, glucose transport activity, and intracellular signaling (9). The activities of D5D and 
D6D appear to be of high relevance for the development of T2D, as higher D5D activity has 
been associated with decreased disease risk, while D6D activity has been directly linked to 
increased risk (41, 42). To our knowledge, this is the first study to examine estimated 
desaturase activities and CVD lipid risk factors in T1D. Given the favorable association 
between D5D and plasma lipids in our sample, further studies are required to better 
understand how the desaturase enzymes relate to cardiovascular health in T1D.
Couch et al. Page 8
J Diabetes Complications. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The strengths of the study include the large, diverse sample of adolescents with T1D studied. 
Additionally, confounding was assessed in our statistical models by including variables 
known to influence fatty acid metabolism-CVD lipid risk factor associations in youth with 
diabetes; however the possibility for residual confounding remains. The repeated measures 
analysis used in this investigation provides increased power over existing cross-sectional 
analyses in examining associations between fatty acid exposures and plasma lipid risk 
factors. Intra-individual variation as well as inter-individual variation was taken into account 
in mixed models, thus providing increased validity for the associations identified. It should 
be noted, however, that the repeated measures analysis is limited in deducing causality. 
Another limitation was the fact that desaturase activities were not directly measured but 
rather estimated using product-to-precursor ratios. Although desaturase activity can be 
measured directly in animals by measurement of the rate of conversion of radiolabeled 
precursor fatty acids to their respective products (7), for ethical and practical reasons it 
cannot be measured in humans. Finally, imputation was used to replace undetectable plasma 
PL PUFAs to avoid bias in the results; best practices were used in this regard.
5. Conclusions
The present study provides novel findings regarding relationships between n-3 and n-6 
PUFAs, desaturases, and plasma lipids/lipoproteins in T1D. Our findings of potential 
beneficial effects of LA, AA and D5D and mixed effects of the n-3 PUFAs, DGLA and D6D 
on plasma lipids suggest interplay between the types of dietary fat consumed, endogenous 
fatty acid synthesis, and diabetes that is important in the development and management of 
the CVD risk profile. The practical interpretation of these data is that vegetable oils rich in 
the most abundant n-6 PUFAs, such as LA rich-corn oil and safflower oil, may provide some 
benefit relative to lipid profile in T1D. Future studies are needed to clarify whether the 
observed associations are related to long-term health outcomes in youth with T1D.
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Figure 1. 
The n-3 and n-6 polyunsaturated fatty acid (PUFA) metabolic pathways where LA = 
Linoleic Acid; DGLA = Dihomo-γ-linolenic acid; AA = Arachidonic acid; ALA =α-
linolenic acid; EPA = Eicosapentaenoic acid; DHA = Docosahexaenoic acid; D5D = delta 5 
desaturation; D6D = delta 6 desaturation; the highlighted PUFAs were those measured in 
plasma phospholipids in the present study.
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Table 1
Baseline demographics and clinical characteristics in youth with Type 1 Diabetes
Characteristic/Measure Total N Mean ± SD or N (%)
Age (years) 914 11.0 (4.0)
Race 914
 African American 90 (9.9)
 Caucasian 721 (78.9)
 Other 103 (11.3)
Gender 914
 Males 478 (52.3)
Diabetes Duration (months) 914 10.9 (6.2)
HbA1c (%) 912 7.8 (1.6)
Insulin dose (Units/kg) 881 0.67 (0.36)
Insulin sensitivity 886 2.3 (0.36)
Insulin regimen type 906
 Pump users 96 (10.6)
 Long + short/rapid, 3 or more x/ day 308 (33.9)
 Other regimens a 502 (55.4)
BMI z-score (kg/m2) 892 0.5 (1.0)
aOther regimens include long acting + any other combination of insulins with injections 2 or more times per day (8%); any combination of insulins 
excluding long acting with injections 3 or more times per day (15%); and any insulin or insulin combinations excluding long acting with injections 
1 or 2 times per day (32%).
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Table 2
Baseline lipid profiles and nutritional exposures in youth with Type 1 Diabetes
Characteristic/Measure Total N Mean ± SD or N (%)
Nutritional Exposures
Plasma Phospholipid Fatty Acids (weight %)
 Linoleic Acid (18:2n-6) 914 25.5 (2.7)
 Di-homo-gamma-linoleic acid (20:3n-6) 914 3.1 (0.7)
 Arachidonic Acid (20:4n-6) 914 13.1 (1.9)
 Alpha-linolenic Acid (18:3n-3) 914 0.2 (0.1)
 Eicosapentanoic Acid (20:5n-3) 914 0.4 (0.3)
 Docosahexaenoic acid (22:6n-3) 914 2.4 (0.8)
Estimated Desaturase Activities
 Delta-5 desaturase (20:4n-6/20:3n-6) 913 4.5 (1.3)
 Delta-6 desaturase (20:3n-6/18:2n-6) 913 0.1 (0.03)
Lipid Profile (mg/dl) 914
 Triglycerides 63.1 (34.7)
 Total cholesterol 162.1 (31.1)
 LDL-cholesterol 95.2 (25.5)
 HDL-cholesterol 54.3 (12.5)
 Triglyceride/HDL-cholesterol ratio 1.3 (0.9)
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